188 related articles for article (PubMed ID: 32886656)
1. A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection.
Furuyama W; Nanbo A; Maruyama J; Marzi A; Takada A
PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008602. PubMed ID: 32886656
[TBL] [Abstract][Full Text] [Related]
2. Fcγ-receptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection.
Furuyama W; Marzi A; Carmody AB; Maruyama J; Kuroda M; Miyamoto H; Nanbo A; Manzoor R; Yoshida R; Igarashi M; Feldmann H; Takada A
PLoS Pathog; 2016 Dec; 12(12):e1006139. PubMed ID: 28036370
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications.
Takada A; Kawaoka Y
Rev Med Virol; 2003; 13(6):387-98. PubMed ID: 14625886
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.
von Kietzell K; Pozzuto T; Heilbronn R; Grössl T; Fechner H; Weger S
J Virol; 2014 Jul; 88(14):8102-15. PubMed ID: 24807719
[TBL] [Abstract][Full Text] [Related]
5. Epitopes required for antibody-dependent enhancement of Ebola virus infection.
Takada A; Ebihara H; Feldmann H; Geisbert TW; Kawaoka Y
J Infect Dis; 2007 Nov; 196 Suppl 2():S347-56. PubMed ID: 17940970
[TBL] [Abstract][Full Text] [Related]
6. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.
Okuya K; Hattori T; Saito T; Takadate Y; Sasaki M; Furuyama W; Marzi A; Ohiro Y; Konno S; Hattori T; Takada A
Microbiol Spectr; 2022 Apr; 10(2):e0155321. PubMed ID: 35319248
[TBL] [Abstract][Full Text] [Related]
7. Antibody-dependent enhancement of Ebola virus infection.
Takada A; Feldmann H; Ksiazek TG; Kawaoka Y
J Virol; 2003 Jul; 77(13):7539-44. PubMed ID: 12805454
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.
Kuzmina NA; Younan P; Gilchuk P; Santos RI; Flyak AI; Ilinykh PA; Huang K; Lubaki NM; Ramanathan P; Crowe JE; Bukreyev A
Cell Rep; 2018 Aug; 24(7):1802-1815.e5. PubMed ID: 30110637
[TBL] [Abstract][Full Text] [Related]
9. Antibody-dependent enhancement of Marburg virus infection.
Nakayama E; Tomabechi D; Matsuno K; Kishida N; Yoshida R; Feldmann H; Takada A
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S978-85. PubMed ID: 21987779
[TBL] [Abstract][Full Text] [Related]
10. HER2-mediated enhancement of Ebola virus entry.
Kuroda M; Halfmann P; Kawaoka Y
PLoS Pathog; 2020 Oct; 16(10):e1008900. PubMed ID: 33052961
[TBL] [Abstract][Full Text] [Related]
11. Ebola virus triggers receptor tyrosine kinase-dependent signaling to promote the delivery of viral particles to entry-conducive intracellular compartments.
Stewart CM; Phan A; Bo Y; LeBlond ND; Smith TKT; Laroche G; Giguère PM; Fullerton MD; Pelchat M; Kobasa D; Côté M
PLoS Pathog; 2021 Jan; 17(1):e1009275. PubMed ID: 33513206
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis.
Thomas S; Smatti MK; Ouhtit A; Cyprian FS; Almaslamani MA; Thani AA; Yassine HM
Mol Immunol; 2022 Dec; 152():172-182. PubMed ID: 36371813
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.
Reynard O; Volchkov VE
J Infect Dis; 2015 Oct; 212 Suppl 2():S372-8. PubMed ID: 26232760
[TBL] [Abstract][Full Text] [Related]
14. Entry of Ebola Virus is an Asynchronous Process.
Reynard O; Volchkov VE
J Infect Dis; 2015 Oct; 212 Suppl 2():S199-203. PubMed ID: 25941332
[TBL] [Abstract][Full Text] [Related]
15. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
Flyak AI; Kuzmina N; Murin CD; Bryan C; Davidson E; Gilchuk P; Gulka CP; Ilinykh PA; Shen X; Huang K; Ramanathan P; Turner H; Fusco ML; Lampley R; Kose N; King H; Sapparapu G; Doranz BJ; Ksiazek TG; Wright DW; Saphire EO; Ward AB; Bukreyev A; Crowe JE
Nat Microbiol; 2018 Jun; 3(6):670-677. PubMed ID: 29736037
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.
Favier AL; Gout E; Reynard O; Ferraris O; Kleman JP; Volchkov V; Peyrefitte C; Thielens NM
J Virol; 2016 Jun; 90(11):5256-5269. PubMed ID: 26984723
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
18. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.
Vu H; Shulenin S; Grolla A; Audet J; He S; Kobinger G; Unfer RC; Warfield KL; Aman MJ; Holtsberg FW
Antiviral Res; 2016 Feb; 126():55-61. PubMed ID: 26681387
[TBL] [Abstract][Full Text] [Related]
19. A Review: Understanding Molecular Mechanisms of Antibody-Dependent Enhancement in Viral Infections.
Sawant J; Patil A; Kurle S
Vaccines (Basel); 2023 Jul; 11(7):. PubMed ID: 37515055
[TBL] [Abstract][Full Text] [Related]
20. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner.
Nanbo A; Imai M; Watanabe S; Noda T; Takahashi K; Neumann G; Halfmann P; Kawaoka Y
PLoS Pathog; 2010 Sep; 6(9):e1001121. PubMed ID: 20886108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
